Health and illness beliefs in adults with tuberculosis infection during the COVID-19 pandemic in the UK.

Covid-19 LTBI health beliefs perceptions tuberculosis

Journal

Dialogues in health
ISSN: 2772-6533
Titre abrégé: Dialogues Health
Pays: United States
ID NLM: 9918506184906676

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 08 08 2023
revised: 23 11 2023
accepted: 27 11 2023
medline: 22 3 2024
pubmed: 22 3 2024
entrez: 22 3 2024
Statut: epublish

Résumé

COVID-19 disrupted the TB prevention programme in the UK, especially for TB infection (TBI) care. We explore whether experience of the COVID-19 pandemic impacted on patients' perceptions of TBI and its treatment. Semi-structured interviews were conducted as part of the Research to Improve Detection and Treatment of TBI (RID-TB) programme, exploring perceptual and practical barriers to TBI treatment. Nineteen people diagnosed with TBI were interviewed between August 2020 and April 2021. Recordings were transcribed and analysed using a constant comparative approach, allowing for a dynamic and iterative exploration of themes. Themes are organised using the Perceptions and Practicalities Approach. Some participants perceived TBI as a risk factor for increased susceptibility to COVID-19, while some thought that treatment for TBI might protect against COVID-19 or mitigate its effects. Adaptations to TB services (e.g., remote follow-up) and integrated practices during the COVID-19 restrictions (e.g., medication being posted) addressed some practical barriers to TBI treatment. However, we identified beliefs about TBI and COVID-19 that are likely to act as barriers to engagement with TBI treatment, including: interpreting service delays as an indication of TBI not being serious enough for treatment and concerns about contracting COVID-19 in TB clinics. COVID-19 and TBI service delays influence people's perceptions and practical barriers to TBI treatment adherence. Failure to address these beliefs may lead to people's concerns about their treatment not being fully addressed. Utilised service adaptations like remote consultations to address practical barriers may be relevant beyond COVID-19. NIHR RID-TB Program (RP-PG-0217-20009).

Sections du résumé

Background UNASSIGNED
COVID-19 disrupted the TB prevention programme in the UK, especially for TB infection (TBI) care. We explore whether experience of the COVID-19 pandemic impacted on patients' perceptions of TBI and its treatment.
Methods UNASSIGNED
Semi-structured interviews were conducted as part of the Research to Improve Detection and Treatment of TBI (RID-TB) programme, exploring perceptual and practical barriers to TBI treatment. Nineteen people diagnosed with TBI were interviewed between August 2020 and April 2021. Recordings were transcribed and analysed using a constant comparative approach, allowing for a dynamic and iterative exploration of themes. Themes are organised using the Perceptions and Practicalities Approach.
Findings UNASSIGNED
Some participants perceived TBI as a risk factor for increased susceptibility to COVID-19, while some thought that treatment for TBI might protect against COVID-19 or mitigate its effects. Adaptations to TB services (e.g., remote follow-up) and integrated practices during the COVID-19 restrictions (e.g., medication being posted) addressed some practical barriers to TBI treatment. However, we identified beliefs about TBI and COVID-19 that are likely to act as barriers to engagement with TBI treatment, including: interpreting service delays as an indication of TBI not being serious enough for treatment and concerns about contracting COVID-19 in TB clinics.
Interpretation UNASSIGNED
COVID-19 and TBI service delays influence people's perceptions and practical barriers to TBI treatment adherence. Failure to address these beliefs may lead to people's concerns about their treatment not being fully addressed. Utilised service adaptations like remote consultations to address practical barriers may be relevant beyond COVID-19.
Funding UNASSIGNED
NIHR RID-TB Program (RP-PG-0217-20009).

Identifiants

pubmed: 38516222
doi: 10.1016/j.dialog.2023.100162
pii: S2772-6533(23)00066-7
pmc: PMC10953974
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100162

Informations de copyright

© 2023 Published by Elsevier Inc. CC BY-NC-ND 4.0.

Déclaration de conflit d'intérêts

None.

Auteurs

Ayşenur Kılıç (A)

School of Pharmacy, University College London, London, UK.

Amy L Clarke (AL)

School of Pharmacy, University College London, London, UK.

Zoe Moon (Z)

School of Pharmacy, University College London, London, UK.

Yohhei Hamada (Y)

Institute for Global Health, University College London, London, UK.

Amy Hai Yan Chan (AHY)

School of Pharmacy, University of Auckland, Auckland, New Zealand.

Ananna Rahman (A)

Department of Respiratory Medicine, Barts Health NHS Trust, London, UK.

Charlotte Layton (C)

MRC Clinical Trials Unit, University College London, UK.

Chris J Griffiths (CJ)

Centre for Primary Care, Wolfson Institute of Population Health, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.

Dominik Zenner (D)

Centre for Primary Care, Wolfson Institute of Population Health, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.

Ellen Powell (E)

MRC Clinical Trials Unit, University College London, UK.

Heinke Kunst (H)

Respiratory Medicine, Queen Mary University of London, London, UK.

Marc Lipman (M)

Royal Free London NHS Foundation Trust, London, UK.
UCL-TB and UCL Respiratory, University College London, London, UK.

Mike Mandelbaum (M)

TB Alert, Brighton, UK.

Padmasayee Papineni (P)

London Northwest University Healthcare NHS Trust, London, UK.

Tessa Tattersall (T)

MRC Clinical Trials Unit, University College London, UK.

Trinh Duong (T)

MRC Clinical Trials Unit, University College London, UK.

Ibrahim Abubakar (I)

Institute for Global Health, University College London, London, UK.

Molebogeng X Rangaka (MX)

Institute for Global Health, University College London, London, UK.
Division of Epidemiology and Biostatistics & CIDRI-AFRICA, University of Cape Town, Cape Town, South Africa.

Robert Horne (R)

School of Pharmacy, University College London, London, UK.

Classifications MeSH